Vanguard FTSE Developed Markets ETF

Most Recent

  • uploads///AdobeStock_
    Consumer

    Where Stanley Druckenmiller Is Bullish

    Last week, Duquesne Family Office, managed by Stanley Druckenmiller, filed its Q3 13F with the SEC. We’ll look at the fund’s top holdings, buys, and sells.

    By Rabindra Samanta
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in May

    GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline’s Pharmaceutical Business in 1Q18

    GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline

    GlaxoSmithKline (GSK) estimates that almost 65% of the global multiple myeloma (or MM) drug sales are realized in the US.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    2-Drug HIV Regimens Expected to Boost GlaxoSmithKline’s Revenues

    GlaxoSmithKline expects to benefit from the commercial expertise obtained from the sale of Tivicay and Triumeq to successfully position Jucala in the HIV market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017

    GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments.

    By Margaret Patrick
  • uploads///Kymriah Juliet
    Company & Industry Overviews

    Key Updates on Novartis’s Kymriah

    In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

    By Daniel Collins
  • uploads///Chart  Alcon
    Earnings Report

    Reading the Estimates for Novartis’s Alcon in 4Q17

    For 4Q17, Alcon is expected to report growth in revenues, driven by the increased demand for contact lenses and surgical products.

    By Mike Benson
  • uploads///Zelboraf
    Company & Industry Overviews

    Zelboraf Could Boost Roche’s Sales Growth in 2018

    Roche’s (RHHBY) Zelboraf (vemurafenib) is indicated for the treatment of individuals with unresectable or metastatic melanoma with the BRAF V600 mutation.

    By Daniel Collins
  • uploads///Polatuzumab
    Company & Industry Overviews

    What to Expect from Roche’s Investigational Drug Polatuzumab Vedotin

    In December 2017, Roche (RHHBY) presented the results of its randomized phase two GO29365 trial.

    By Daniel Collins
  • uploads///Hemlibra
    Company & Industry Overviews

    How Is Roche’s Hemlibra Positioned for 2018?

    Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

    By Daniel Collins
  • uploads///new generation insulin
    Company & Industry Overviews

    Novo Nordisk’s Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018

    Novo Nordisk’s (NVO) Xultophy (insulin degludec and liraglutide combination) is used as an addition to diet and exercise for improvement of blood sugar levels in adults with type-2 diabetes mellitus whose blood sugar level could not be controlled adequately with basal insulin.

    By Daniel Collins
  • uploads///Symbicort revenues
    Company & Industry Overviews

    How Did AstraZeneca’s Respiratory Drug Symbicort Perform in 2017?

    In 9M17, Symbicort’s revenues from emerging markets witnessed 7.0% growth to reach $322.0 million.

    By Daniel Collins
  • uploads///Tagrisso
    Company & Industry Overviews

    AstraZeneca’s Tagrisso Witnessed High Growth in 3Q17

    In 3Q17, AstraZeneca’s (AZN) Tagrisso generated revenues of $248.0 million, which reflected ~86.0% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Chart  Ratings
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in November 2017

    Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.

    By Mike Benson
  • uploads///A VanEck
    Real Insights

    A Peek into the MOTI ETF’s Performance

    While MOTI’s performance these past 12 months alone has been notable, its returns since inception have been equally impressive.

    By VanEck
  • uploads///Gazyva
    Company & Industry Overviews

    How Roche’s Oncology Drug Gazyva Is Positioned after 3Q17

    In 3Q17, Roche’s (RHHBY) Gazyva generated revenues of 69 million Swiss francs, which reflected ~34% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Rituxan
    Company & Industry Overviews

    Roche’s Blockbuster Drugs Avastin and Rituxan after 3Q17

    In 3Q17, Roche Holding’s (RHHBY) Avastin generated revenues of 1.6 million Swiss francs, which reflected a ~4% fall on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Perjeta and Herceptin
    Company & Industry Overviews

    Perjeta Could Drive Roche’s Long-Term Growth

    In June 2017, Roche (RHHBY) presented the results from the Phase 3 APHINITY trial.

    By Daniel Collins
  • uploads///Novo Nordisk revenues
    Company & Industry Overviews

    How Novo Nordisk Performed in the 1st Half of 2017

    In the first half of 2017, Novo Nordisk (NVO) reported revenues of $8.3 billion compared to $8.2 billion in the first half of 2016. In 2Q17, it generated revenues of $4.2 billion.

    By Daniel Collins
  • uploads///Novartis revenues
    Company & Industry Overviews

    How Did Novartis Perform in 1H17?

    In 1H17, Novartis (NVS) reported revenues of around $23.8 billion, a ~1% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Chart  EPS
    Company & Industry Overviews

    Changes in AstraZeneca’s Valuation after Its 2Q17 Earnings

    AstraZeneca’s (AZN) stock value has fallen ~11.9% over the last 12 months. Wall Street analysts estimate that the stock has the potential to return ~16.6% over the next 12 months.

    By Mike Benson
  • uploads///CP Carloads
    Miscellaneous

    How Canadian Pacific Railway’s Volumes Compared to Peers

    Canadian Pacific Railway (CP) is Canada’s second-largest freight rail.

    By Samuel Prince
  • uploads///Chart  SWR
    Company & Industry Overviews

    How Did GlaxoSmithKline’s Segments Perform in 2Q17?

    GlaxoSmithKline’s Pharmaceuticals segment reported revenues of 4.36 billion pounds during 2Q17—12% growth compared to 2Q16.

    By Mike Benson
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    Behind Novartis’s Valuation after 2Q17

    Novartis missed the analysts’ estimate for 2Q17 revenues, reporting $12.24 billion and falling short of $12.27 billion, but surpassed the estimate for EPS.

    By Mike Benson
  • uploads///CP Carloads
    Miscellaneous

    Canadian Pacific Railway: Rise in Railcars Cover Intermodal Fall in Week 33

    Canadian Pacific Railway witnessed a volume loss in the intermodal space in week 33 of 2017.

    By Samuel Prince
  • uploads///Graph
    Company & Industry Overviews

    How Analysts View Fresenius Medical Care and Its Peers in August 2017

    In 1H17, Fresenius Medical Care (FMS) reported revenues close to 9.0 billion euros, which represents 14% YoY growth. At the end of 2Q17, the company operated 3,690 dialysis clinics around the world.

    By Margaret Patrick
  • uploads///Chart  Rev
    Earnings Report

    GlaxoSmithKline’s 2Q17 Earnings Reveal Growth

    In its earnings release on July 26, GlaxoSmithKline (GSK) reported 12% growth to ~7.3 billion pounds in its 2Q17 revenues. GSK surpassed analysts’ estimates for revenues and earnings per share.

    By Mike Benson
  • uploads///Chart  Ratings
    Earnings Report

    GlaxoSmithKline on the Street: Analyst Recommendations after 2Q17

    Wall Street analysts estimate that GSK’s top line will rise 11.4% to ~7.3 billion British pounds for 2Q17. Its EPS is expected come in at 0.26 pounds.

    By Mike Benson
  • uploads///Chart  Rev EPS
    Earnings Report

    Novartis: Here’s What Impacted 2Q17 Earnings and Missed Estimates

    Novartis (NVS) released its 2Q17 earnings on July 18, 2017. It reported flat revenues at constant exchange rates compared to 2Q16.

    By Mike Benson
  • uploads///Chart  SNY
    Miscellaneous

    How Sanofi Stock Performed in 2Q17

    Sanofi (SNY) stock has risen ~4.2% in 2Q17 and 16.8% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Imfinzi May Be AstraZeneca’s Major Growth Driver

    Currently, AstraZeneca is exploring the efficacy of Imfinzi in early stage NSCLC in an adjuvant setting.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analyst Recommendations for AstraZeneca in June 2017

    In 1Q17, AstraZeneca (AZN) reported revenues close to $5.4 billion, which is a fall of around 12.0% on a YoY (year-over-year) basis.

    By Margaret Patrick
  • uploads///bond yeilds
    Macroeconomic Analysis

    How Did Fixed Income Markets React to the First Round?

    Demand for fixed income securities will likely be subdued because of excess supply this week, which would mean additional support for bond yields.

    By Ricky Cove
  • uploads///Graph
    Company & Industry Overviews

    Consistent Performance Measurement May Improve Novartis’s R&D

    Novartis (NVS) has been focused on consistently measuring the performance of its research and development (or R&D) programs using metrics such as output, cost, returns, quality, and cycle time.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Have Novartis’s Valuation Multiples Fallen?

    Despite patent expiries worth $2.4 billion, Novartis (NVS) managed to report a flat revenue performance in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Entresto Could See Steep Rise in Total Prescriptions This Year

    Novartis’s (NVS) heart failure drug, Entresto, has been witnessing a steep rise in both new to brand prescriptions as well as total prescriptions in the US market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What to Expect from AstraZeneca’s Farxiga in 2017

    Despite intense competition, AstraZeneca (AZN) managed to report 11% year-over-year (or YoY) revenue growth for its diabetes franchise in 2016.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Segment-Wise Performance in Fiscal 2016

    At constant exchange rates, AstraZeneca (AZN) reported an 8% decline in its product sales to ~$21.3 billion during fiscal 2016, as well as a 15% decline in its 4Q16 product sales to ~$5.3 billion.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s Focused Strategy to Boost Future Revenues

    If AstraZeneca’s focused strategy enables it to report a solid revenue performance, it may have a positive impact on its share prices.

    By Margaret Patrick
  • uploads///Abenomics
    Company & Industry Overviews

    What Paul Krugman Thinks about Japan’s Yield Curve Control Policy

    In its latest policy move, the Bank of Japan left rates unchanged and delayed inflation target timings for the Japanese economy (EWJ) (HEWJ) (DXJ).

    By Surbhi Jain
  • uploads///pound
    Company & Industry Overviews

    Paul Krugman: Not the Time to Hike Rates in Great Britain

    Paul Krugman is among those who believed that Brexit wouldn’t affect the UK economy negatively.

    By Surbhi Jain
  • uploads///japanification of china
    Company & Industry Overviews

    Krugman: We’re Seeing ‘Japanification’ of Developed World and China

    Paul Krugman says he’s witnessing the “Japanification” of the developed world (EFA) (VEA).

    By Surbhi Jain
  • uploads///Chart
    Earnings Report

    AstraZeneca’s Other Products in 3Q16

    With lower sales from blockbuster drugs Nexium and Seroquel, the contribution of AstraZeneca’s (AZN) Other segment fell to ~21.2% in 3Q16.

    By Mike Benson
  • uploads///global market reaction to DT win
    Financials

    Global Markets React as Trump Wins the 2016 US Election

    The results of the general election are out: Republican nominee Donald Trump has won the 2016 US presidential election.

    By Surbhi Jain
  • uploads///polls data nov
    Financials

    A Trump Presidency: What Are the Odds?

    With Hillary Clinton leading Donald Trump in the polls before Tuesday’s US presidential election, the projected results are still uncertain. However, a Trump victory may not be good news for those invested in emerging markets.

    By Surbhi Jain
  • uploads///policy tools
    Financials

    Dalio: What Policies Are Required of Central Bankers?

    Ray Dalio: Here’s what’s required of central bankers Given the inadequacy of monetary policy measures to stimulate the economy, we may see “more direct placements of purchasing power in the hands of spenders,” believes Ray Dalio. He has outlined what central bankers should do. “Continue to make debt assets extremely unattractive for savers” For some […]

    By Surbhi Jain
  • uploads///key rates
    Financials

    Central Bankers Facing ‘Pushing on a String’ Situation

    Central bankers are maxing out on their debt limit “There is only so much one can squeeze out of a debt cycle,” believes Ray Dalio, and central bankers seem to be maxing out on that limit. “In other words, they are simultaneously approaching both their debt limits and central banks’ ‘pushing on a string’ limits,” […]

    By Surbhi Jain
  • uploads///negative debt as prop of GDP
    Financials

    Bill Gross Explains Why Central Bankers Can’t Keep Raising Stakes

    In his investment outlook for October 2016, Bill Gross of Janus Capital (JNS) compared the central bankers’ recent monetary policy measures to wagers placed at a betting game.

    By Surbhi Jain
  • uploads///Yield Curve Is Steepening
    Company & Industry Overviews

    Yield Curve Is Steepening: What Does It Indicate for the Market?

    In this series, we’ll compare yields across various developed markets (EFA) (VEA). We’ll also look at how a steepening yield curve affects the financial sector (XLF).

    By Sarah Sands
  • uploads///latin america price performance
    Company & Industry Overviews

    Investing in Latin America Can Bear Fruit, but Should We?

    With commodity prices recovering and major developed markets (EFA) (VEA) caught in the lull, Latin America should see sunnier days ahead.

    By Surbhi Jain
  • uploads///student debt and age
    Financials

    Millennials or Baby Boomers: Who’s Affected Most by Student Debt?

    The Baby Boomer generation has also been increasingly contributing to the student debt crisis.

    By Surbhi Jain
  • uploads///fcau pm
    Company & Industry Overviews

    Fiat Chrysler’s July 2016 Sales in Focus

    Fiat Chrysler Automobiles (FCAU) fell by 4.0% to close at $6.08 per share on August 2, 2016.

    By Gabriel Kane
  • uploads///ifo
    Macroeconomic Analysis

    Why Did Ifo’s Release Show Gains in Construction and Retail?

    The overall Ifo business climate suffered a setback in July. Looking at the sector-based performance, the construction and retail sector saw a rise.

    By David Meyer
  • uploads///Inflation Interest Rates and FX
    Macroeconomic Analysis

    How Are Inflation, Interest Rates, and Foreign Exchange Related?

    A low rate of inflation doesn’t guarantee a favorable exchange rate. But a high inflation rate is likely to have a negative effect on a currency’s value.

    By Heather McArdle
  • uploads///euro
    Miscellaneous

    How Did Mario Draghi’s Statement Impact the Euro?

    Mario Draghi was less dovish in the post monetary policy press conference. The press conference started 45 minutes after the monetary policy statement.

    By David Meyer
  • uploads///fcau pm
    Company & Industry Overviews

    Moody’s Upgraded Fiat Chrysler’s Ratings

    Fiat Chrysler Automobiles (FCAU) has a market cap of $8.5 billion. It fell by 2.5% to close at $6.56 per share on July 19, 2016.

    By Gabriel Kane
  • uploads///german
    Macroeconomic Analysis

    Inflation Rises in United Kingdom: Should Go Higher on Weak Pound

    Inflation rate in the United Kingdom pushed higher to release at 0.5% on an annual basis in June. However, it was still below the central bank’s target of 2%.

    By David Meyer
  • uploads///imf
    Miscellaneous

    Outlook Projections: IMF Cuts Global Growth Forecasts

    The IMF cut its global economic growth forecasts, according to the latest IMF World Economic Output Update dated July 19. The cut in forecasts was expected.

    By David Meyer
  • uploads///asian
    Macroeconomic Analysis

    Why Are Global Markets Range Bound?

    The contrasting movement among the global markets was primarily due to caution ahead of the Bank of England’s monetary policy release on July 14.

    By David Meyer
  • uploads///european
    Macroeconomic Analysis

    Markets Extend Rally on Stimulus Hopes, FTSE 100 Remains Flat

    The FTSE 100, the United Kingdom’s major index (EWU), has been on rising trend after the sharp fall for two days following the Brexit referendum.

    By David Meyer
  • uploads///fcau pm
    Company & Industry Overviews

    Why Is Levi & Korsinsky Investigating Fiat Chrysler Automobiles?

    Fiat Chrysler Automobiles (FCAU) has a market cap of $8.2 billion. It rose by 4.4% to close at $6.39 per share on July 11, 2016.

    By Gabriel Kane
  • uploads///bank lending
    Financials

    What If Low Interest Rates Don’t Result in Increased Lending?

    With most of the developed world at near zero or negative yields, the contribution of lowering interest rates to the velocity of money is diminishing.

    By Surbhi Jain
  • uploads///central bankers as the community chest
    Financials

    Bill Gross: Unfortunately, We Aren’t Playing Monopoly

    In Monopoly, the $200 of credit creation never changes. In the real economy, credit creation isn’t guaranteed to occur at the same pace each year.

    By Surbhi Jain
  • uploads///fcau pm
    Company & Industry Overviews

    How Did Fiat Chrysler Automobiles Perform in Canada and Italy?

    Fiat Chrysler Automobiles’ (FCAU) stock fell by 1.9% to close at $6.12 per share during the first week of July 2016.

    By Gabriel Kane
  • uploads///fcau pm
    Company & Industry Overviews

    Barclays Downgrades Fiat Chrysler to ‘Underweight’

    Fiat Chrysler Automobiles (FCAU) has a market cap of $7.4 billion. It rose by 0.35% to close at $5.70 per share on July 6, 2016.

    By Gabriel Kane
  • uploads///european
    Macroeconomic Analysis

    Weak Data Puts Downward Pressure on European Indexes

    On July 6, major European indexes were trading lower for the second day. The fall in the indexes was led by the Italian FTSE MIB and the UK-based FTSE 100.

    By David Meyer
  • uploads///asia
    Macroeconomic Analysis

    Are Global Indexes Pointing to a Weak Start for US Markets?

    The fall in European markets was led by the German DAX and the French CAC 40—they fell by 1.3% and 1.4%, respectively.

    By David Meyer
  • uploads///asian
    Macroeconomic Analysis

    Does the FTSE 100 Reflect the United Kingdom’s Economic Sentiment?

    The FTSE 100 had a rollercoaster ride in the previous month. The index fell to a low of 5,788.74 on the day of the United Kingdom’s referendum results.

    By David Meyer
  • uploads///european
    Macroeconomic Analysis

    FTSE 100 Leads the Gains in Global Markets

    On June 29, the rise in European indexes was led by the United Kingdom’s index FTSE 100. It suffered the most since Brexit. The FTSE 100 rose by 3.6%.

    By David Meyer
  • uploads///SP  Buyback Index Outperformed SP  Index
    Financials

    Icahn Identifies a Key Motivation behind the Buyback Spree in the US

    Carl Icahn is one of the first activist investors to voice his opinion against share buybacks. He believes that companies are increasingly putting money into buybacks instead of using them for much-needed capital improvements.

    By Surbhi Jain
  • uploads///bridgewater top
    Financials

    Ray Dalio Suggests Emerging Markets, and George Soros Says Gold, but What’s Your Pick?

    On June 24, the developed markets (EFA) (VEA) recorded an 8.6% dip, as compared to the emerging markets (EEM) (VWO), which dipped by 6%.

    By Surbhi Jain
  • uploads///GBP  year
    Macroeconomic Analysis

    Pound Sterling Falls to 30-Year Lows as Britain Exits the EU

    Following Britain’s exit from the European Union, the pound sterling fell by more than 10% on June 24 as traders maintained their sell positions on the British pound.

    By David Meyer
  • uploads///phg pm
    Company & Industry Overviews

    Philips Acquires PathXL to Expand Its Business

    Koninklijke Philips (PHG) has a market cap of $24.5 billion. It rose by 1.8% and closed at $26.15 per share on June 21, 2016.

    By Gabriel Kane
  • uploads///fcau pm
    Company & Industry Overviews

    Fiat Chrysler Rose with Its Electric Vehicle Plan

    Fiat Chrysler Automobiles rose by more than 4.1% on June 20, 2016, after the news that it is planning to add full electric vehicles in its product line.

    By Gabriel Kane
  • uploads///fcau pm
    Company & Industry Overviews

    How Were Fiat Chrysler’s Sales in May?

    Fiat Chrysler Automobiles (FCAU) fell by 1.6% to close at $6.76 per share at the end of the third week of June 2016.

    By Gabriel Kane
  • uploads/// Top  MR Country ETF Flows
    Miscellaneous

    Why Country ETFs Are Facing Currency Impacts and Taper Fears

    Do flows trickle into Japan as emerging market currency fears loom once again?

    By Meikel Mokry
  • uploads///phg pm
    Company & Industry Overviews

    Philips Announced the Pricing of Its Lighting IPO

    Koninklijke Philips (PHG) raised 750 million euros ($839 million) from its initial public offering (or IPO) of its Lighting business.

    By Gabriel Kane
  • uploads///phg pm
    Company & Industry Overviews

    Exane BNP Paribas Upgrades Koninklijke Philips to ‘Outperform’

    Koninklijke Philips (PHG) has a market cap of $24.7 billion. It fell by 0.94% to close at $26.48 per share on May 11, 2016.

    By Gabriel Kane
  • uploads///phg pm
    Earnings Report

    Koninklijke Philips Reported Mixed Quarterly Results for 1Q16

    Koninklijke Philips (PHG) has a market cap of $25.4 billion. PHG fell by 4.2% to close at $27.09 per share on April 25, 2016.

    By Gabriel Kane
  • uploads///SP  Buyback Index Outperformed SP  Index
    Macroeconomic Analysis

    Share Buybacks: Lower Valuation or Cheap Capital?

    By reducing the number of outstanding shares, companies increase the EPS. Through share buybacks, companies return more cash to shareholders.

    By Sarah Sands
  • uploads///japan inflation rate
    Macroeconomic Analysis

    Is Japan at the Tipping Point of Quantitative Easing?

    The central bank in Japan seems to have reached the limit to which it can exercise QE in the economy. Quantitative easing certainly seems at a tipping point in this developed market.

    By Surbhi Jain
  • uploads///CTAs performed when equities slumped
    Miscellaneous

    Why Commodity Trading Advisors Fare Well When Nothing Else Works

    CTAs (commodity trading advisors) offer diversification benefits (commodity exposure when the equity markets are down), along with liquidity.

    By Surbhi Jain
  • uploads///mexico top exports
    Macroeconomic Analysis

    Consumerism Abroad to Drive Growth in Mexico

    Mexico is known for its industrial base. In 2015, vehicles constituted about 23.7% of Mexican exports, followed by electronic equipment at 21.3% of exports.

    By Surbhi Jain
  • uploads///demographics latam
    Company & Industry Overviews

    What Will Drive Growth in Latin America?

    Emerging markets, notably economies in Latin America, have a younger population than the developed world.

    By Surbhi Jain
  • uploads///unemployment gap
    Macroeconomic Analysis

    Labor Market Slack Impacts Prices and Wages

    If the unemployment gap is declining and the participation gap is rising, it could be due to an increase in labor market slack.

    By Surbhi Jain
  • uploads///Israels Economy Has Grown at a Steady Pace
    Macroeconomic Analysis

    Why Israel’s Economy Is Still Resilient

    Israel’s government debt as a proportion of gross national product has declined steadily this century.

    By Aberdeen Closed-End Funds
  • uploads///Commodity deflation
    Macroeconomic Analysis

    In the Current Deflation Spiral, Flat Is the New Up

    There’s a currency war going on that is only adding fuel to the deflation situation. In fact, currency warfare is often a way that deflation gets exported.

    By Surbhi Jain
  • uploads///Euro
    Macroeconomic Analysis

    Eurozone Manufacturing Eased in January

    In-line with the flash estimate, the Eurozone’s manufacturing PMI (purchasing manufacturers’ index) stood at 52.3 in January 2016.

    By Lara Sheldon
  • uploads///sne pm
    Earnings Report

    Sony’s Revenue and Income Rose in 3Q15

    Sony (SNE) has a market cap of $29.8 billion. SNE rose by 17.7% to close at $23.88 per share as of January 29, 2016.

    By Gabriel Kane
  • uploads///Japan hsg
    Macroeconomic Analysis

    The Japanese Housing Sector Sent a Mixed Signal in December

    According to the Ministry of Land, Infrastructure and Transport, Japanese housing starts fell 1.3% in December YoY as compared to a rise of 1.7% in November.

    By Lara Sheldon
  • uploads///CHina debt to GDP
    Fund Managers

    George Soros Sees a Crisis like 2008: This Time It’s China!

    According to George Soros, China has taken too long to change from an investment and export-driven growth model to a domestic consumption-driven one.

    By Surbhi Jain
  • uploads///Eurozone
    Macroeconomic Analysis

    Eurozone Flash Composite PMI Fell 53.5, Business Activity Cools

    With the reading above neutral, the Eurozone continued its upturn in business activity. Though at a 12-month low, the services PMI rose to 53.6 in January

    By Lara Sheldon
  • uploads///France
    Macroeconomic Analysis

    Seasonal Rise in Services Boosted French Inflation

    France’s CPI (consumer price index) rose 0.2% month-over-month in December, as compared to a 0.2% decline in November 2015.

    By Lara Sheldon
  • uploads///France
    Macroeconomic Analysis

    France’s Services Business Activity Stagnated in December 2015

    The service sector makes up about 78.9% of the French economy. According to Markit, France’s services business activity index declined by 1.2 points in December to 49.8.

    By Lara Sheldon
  • uploads///sne pbv
    Company & Industry Overviews

    How Does Sony Compare to Its Peers?

    The Vanguard FTSE Pacific ETF (VPL) invests 0.56% of its holdings in Sony.

    By Gabriel Kane
  • uploads///sne pm
    Company & Industry Overviews

    Sony Fell on Falling Apple iPhone Production

    Sony (SNE) has a market capitalization of $30.2 billion. SNE fell by 7.2% to close at $23.63 per share on January 6, 2016.

    By Gabriel Kane
  • uploads///sne pe
    Company & Industry Overviews

    How Does Sony Corporation Compare to Its ETFs and Peers?

    Sony Corporation’s peers have mostly outperformed it based on price-to-book value. However, Sony is ahead of its peers based on price-to-earnings.

    By Gabriel Kane
  • uploads///sne pm
    Company & Industry Overviews

    Organic Growth Boosts Sony’s Stock

    Sony’s stock price movements on a weekly, monthly, and year-to-date (or YTD) basis are 3.2%, 0.87%, and 3.5%, respectively.

    By Gabriel Kane
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.